If you have been diagnosed with non-melanoma skin cancer, learn more about a gentler way to treat skin cancer.
Published Research on the Use of Image-Guided Superficial Radiation Therapy (IG-SRT) in the Treatment of Nonmelanoma Skin Cancer (NMSC)
See the growing clinical evidence supporting the use of Image-Guided Superficial Radiation Therapy (Image-Guided SRT) as a first-line treatment option for patients with NMSC.
Yu L, et al. Oncol Ther. 2021;9(1):153-166.
Retrospective chart review evaluating LC rates of 1632 patients with 2917 stage 0-II carcinomas
99.3% local control rates with an industry-proven, 20-faction protocol—IG-SRT is safe and tolerable and should be considered a first-line option for NMSC
Cure rates observed in this initial period of follow-up are similar, and potentially superior with further follow-up, to traditional SRT and surgical options.
Yu L, et al. Discov Oncol. 2022;13(1):129.
Meta-analysis comparing local control rates of 2 seminal studies that used high-resolution dermal ultrasound-guided SRT (US-SRT) with 4 studies that used traditional non–image-guided radiotherapy (XRT and SRT) in the treatment of NMSC
Local control rates for the 2 US-SRT studies were statistically superior to the 4 traditional therapies individually and collectively. When stratified by histology, statistically superior outcomes for US-SRT were observed in all subtypes
US-SRT is statistically superior to non–image-guided radiotherapies for NMSC treatment. This modality may represent the future standard of non-surgical treatment for early-stage NMSC.
Yu L, et all. BMC Cancer. 2023;23(1):98.
Logistic regression analysis comparing local control rates found in 4 studies using non–image-guided radiotherapy to LC rates of a study that used US-SRT, with stratification by histology (BCC, SCC, and SCCIS)
Local control rates with US-SRT were statistically superior to those found in studies using non–image-guided radiation therapy, individually and comparatively and across histological subtypes, with P-values ranging from P<.0001 to P=.0438
Image guidance with high resolution dermal ultrasound in the form of US-SRT is shown to confer a statistically significant advantage in lesion local control over non–image-guided forms of SRT or XRT in all subtypes of cutaneous epithelial NMSC and should be considered the preferred standard of non-surgical treatment for early-stage cutaneous BCC, SCC, and SCCIS.
Tran A, et al. J Cancer Res Clin Oncol. 2023.
Retrospective chart review evaluating local control rates of 1243 patients with 1899 stage 0-II NMSC (BCC, SCC, and SCCIS) who received treatment with IG-SRT energies ranging from 50 to 100 kV, for a mean of 20.2 fractions, and treatment dose of 5364.4 cGy
99.7% of patients achieved absolute lesion local control after an average of 7.5 weeks of treatment, 99.6% of patients achieved stable control with >12 months follow-up, and 95% of lesions had a RTOG score of 1 or 2
IG-SRT has a high safety profile, can achieve superior cosmesis and should be considered first-line for treating early-stage NMSC tumors as cure rates have been shown to be effective in all NMSC on early follow-up…making it a safe, and potentially cost-effective option for NMSC treatment compared to surgery.
Tran A, Yu L. J Dermaol Skin Sci. 2022;4(4):6-8.
Review of the evidence supporting the potential for IG-SRT to improve access to skin cancer treatment in poor and rural communities
- Skin cancer is the most common cancer in the United States, with incidence rates of melanoma and NMSC on the rise
- Reduced access to cancer treatment and long travel times may contribute to poor outcomes for patients in non-metropolitan counties
- Collaboration across care providers can address disparities in access to oncodermatologic care (dermatologists, surgeons, otolaryngologists, radiation oncologists, and radiation therapists)
- With favorable clinical and cosmetic outcomes, tolerable side effects, and flexibility in treatment administration locations, IG-SRT may help improve access to skin cancer treatment in poor and rural communities
The use of modern superficial radiation therapy might address disparities in dermatologic care.
See the Difference In Partnering with SkinCure Oncology
See the Difference In Partnering with SkinCure Oncology
Interested in making Image-Guided SRT a treatment option at your practice? Contact us to discuss all the ways SkinCure Oncology can help.